CS
NAVB

Credit Suisse’s Navidea Biopharmaceuticals Inc. NAVB Stock Holding History

Credit Suisse’s Portfolio NAVB Stock Details NAVB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-20,421
Closed -$217K – 4345
2016
Q2 		$217K Buy
20,421
+19,411
+1,922% +$381K ﹤0.01% 3836
2016
Q1 		$19K Sell
1,010
-3,126
-76% -$60.2K ﹤0.01% 3928
2015
Q4 		$110K Buy
4,136
+1,671
+68% +$58K ﹤0.01% 4061
2015
Q3 		$112K Buy
2,465
+108
+5% +$4.07K ﹤0.01% 4085
2015
Q2 		$75K Buy
2,357
+1,429
+154% +$41.5K ﹤0.01% 4425
2015
Q1 		$29K Sell
928
-1,787
-66% -$60.5K ﹤0.01% 4307
2014
Q4 		$103K Buy
2,715
+2,032
+298% +$55.9K ﹤0.01% 4429
2014
Q3 		$17K Sell
683
-2,796
-80% -$74K ﹤0.01% 4400
2014
Q2 		$103K Sell
3,479
-2,199
-39% -$71.1K ﹤0.01% 4531
2014
Q1 		$211K Sell
5,678
-1,298
-19% -$49.2K ﹤0.01% 4322
2013
Q4 		$289K Buy
6,976
+4,169
+149% +$163K ﹤0.01% 4103
2013
Q3 		$149K Sell
2,807
-1,503
-35% -$87.6K ﹤0.01% 4048
2013
Q2 		$230K Buy
+4,310
New +$215K ﹤0.01% 3799

Other funds holding NAVB

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $14.7B AUM 47% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
California Public Employees Retirement System
California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return

Credit Suisse's NAVB Position: Q3 2016 in Review

Credit Suisse sold out of Navidea Biopharmaceuticals Inc. (NAVB) in Q3 2016, closing a stake of 20,421 shares — an estimated $217K sold.

Credit Suisse first reported a position in NAVB in Q2 2013 and held it in 13 quarters. The position peaked at $289K in Q4 2013. 55 funds tracked by Wall St. Rank hold NAVB as of Q3 2016.

  • Credit Suisse reported no remaining Navidea Biopharmaceuticals Inc. position as of Q3 2016 after selling out during the quarter.
  • Credit Suisse sold 20,421 Navidea Biopharmaceuticals Inc. shares in Q3 2016, an estimated $217K.
  • Credit Suisse first reported a position in Navidea Biopharmaceuticals Inc. in Q2 2013 and held it in 13 quarters.
  • Credit Suisse's Navidea Biopharmaceuticals Inc. position peaked at $289K in Q4 2013.
  • 55 funds tracked by Wall St. Rank held Navidea Biopharmaceuticals Inc. as of Q3 2016.

Based on Credit Suisse's 13F filing for Q3 2016, filed 15 Nov 2016.